There's already the confirmation we need, the sales growth and financial performance has been phenomenal and has been sustained. The market will take time, but it'll happen sooner or later this will get the rerate it deserves. Substantially undervalued based on all fundamental metrics, the numbers don't lie. Nothing has been priced in, but it will eventually.
The results later this month should hopefully do the trick.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-395
-
- There are more pages in this discussion • 113 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $44.66M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $9.907K | 50.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 65104 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 51773 | 2 |
View Market Depth
| Last trade - 13.43pm 13/09/2024 (20 minute delay) ? |
| EYE (ASX) Chart |